Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33024
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChin, Kai Sin-
dc.contributor.authorChurilov, Leonid-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorYassi, Nawaf-
dc.contributor.authorWatson, Rosie-
dc.date2023-
dc.date.accessioned2023-06-07T02:47:18Z-
dc.date.available2023-06-07T02:47:18Z-
dc.date.issued2024-02-
dc.identifier.citationThe Australian and New Zealand Journal of Psychiatry 2024-02; 58(2)en_US
dc.identifier.issn1440-1614-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33024-
dc.description.abstractNeurofibrillary tangles are present in a proportion of people with dementia with Lewy bodies and may be associated with worse cognition. Recent advances in biomarkers for Alzheimer's disease include second-generation tau positron emission tomography as well as the detection of phosphorylated tau at threonine 181 (p-tau181) in plasma. This study aimed to investigate tau in people with dementia with Lewy bodies using a second-generation tau positron emission tomography tracer as well as plasma p-tau181. Twenty-seven participants (mean age 74.7 ± 5.5) with clinically diagnosed probable dementia with Lewy bodies underwent comprehensive clinical assessment and positron emission tomography imaging (18F-MK6240 and 18F-NAV4694). Plasma p-tau181 levels were measured using Simoa technology. Five dementia with Lewy bodies participants (18.5%) had an abnormal tau positron emission tomography (increased tau uptake in the temporal meta-region-of-interest). Higher plasma p-tau181 concentrations correlated with higher tau deposition in the temporal region (ρ = 0.46, 95% confidence interval = [0.10, 0.72]) and classified abnormal tau positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.95 (95% confidence interval = [0.86, 0.99]). Plasma p-tau181 also correlated positively with cortical amyloid-beta binding (ρ = 0.68, 95% confidence interval = [0.40, 0.84]) and classified abnormal amyloid-beta positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.91 (95% confidence interval = [0.79, 0.99]). There was no association found between tau deposition and any of the clinical variables. Tau is a common co-pathology in dementia with Lewy bodies. Plasma p-tau181 correlated with abnormal tau and amyloid-beta positron emission tomography and may potentially be used as a marker to identify co-morbid Alzheimer's disease-related pathology in dementia with Lewy bodies. The clinical implications of tau in dementia with Lewy bodies need to be further evaluated in larger longitudinal studies.en_US
dc.language.isoeng-
dc.subjectAlzheimer’s diseaseen_US
dc.subjectTauen_US
dc.subjectdementia with Lewy bodiesen_US
dc.subjectphosphorylated tauen_US
dc.subjectpositron emission tomographyen_US
dc.titleTau in dementia with Lewy bodies.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Australian and New Zealand Journal of Psychiatryen_US
dc.identifier.affiliationDepartment of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.en_US
dc.identifier.affiliationMolecular Imaging and Therapyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationPopulation Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Aged Care, The Royal Melbourne Hospital, Parkville, VIC, Australiaen_US
dc.identifier.affiliationHealth and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Clayton South, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.en_US
dc.identifier.doi10.1177/00048674231177219en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-3384-3499en_US
dc.identifier.pubmedid37264610-
dc.description.startpage48674231177219-
local.name.researcherChurilov, Leonid-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

64
checked on Nov 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.